Alzheimer's, Parkinson's, ALS — these diseases have been notoriously hard to treat. But small molecules are making a comeback. The small molecule drug discovery market research shows that neurological disorders are the fastest‑growing therapeutic area, with a CAGR above 10%. Why? Because new targets (tau, alpha‑synuclein) are being validated, and AI is helping design molecules that cross the blood‑brain barrier.
What's the challenge? The brain is hard to reach. Most small molecules can't get past the blood‑brain barrier. But new chemistry (lipidation, nanoparticle carriers) is overcoming that. The small molecule drug discovery market trends highlight that pharmaceutical companies are the largest end‑user segment, but contract research organizations (CROs) are the fastest‑growing — as biotechs outsource discovery to specialists.
Recent breakthroughs: a small molecule that reverses cognitive decline in Alzheimer's mice, and another that slows Parkinson's progression. Human trials are underway.
The bottom line: neurological drug discovery is risky, but the payoff is huge. If you're an investor, watch this space.
